ProQR Therapeutics N.V. (PRQR) stock
PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.15−0.03 (-2.54%)
Close on Nov 17, 2026Market cap $121.17MP/E –Yield –
ProQR Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
ProQR Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was €45.50M, up 4.0% year over year. For fiscal 2025 it was €44.73M, up 23.0% from the year before. Over ten years it grew 6.7% a year on average. The highest annual figure on record is €50.87M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €44.73M | +23.0% |
| FY2024 | Dec 31, 2024 | €36.36M | +44.6% |
| FY2023 | Dec 31, 2023 | €25.15M | -50.6% |
| FY2022 | Dec 31, 2022 | €50.87M | +20.5% |
| FY2021 | Dec 31, 2021 | €42.22M | +10.7% |
| FY2020 | Dec 31, 2020 | €38.14M | -18.0% |
| FY2019 | Dec 31, 2019 | €46.49M | +57.5% |
| FY2018 | Dec 31, 2018 | €29.51M | -5.3% |
| FY2017 | Dec 31, 2017 | €31.15M | -2.4% |
| FY2016 | Dec 31, 2016 | €31.92M | +36.4% |
| FY2015 | Dec 31, 2015 | €23.40M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €12.67M | +11.0% |
| Q1 FY2026 | Mar 31, 2026 | €11.83M | -4.0% |
| Q4 FY2025 | Dec 31, 2025 | €9.92M | -6.5% |
| Q3 FY2025 | Sep 30, 2025 | €11.08M | +17.7% |
| Q2 FY2025 | Jun 30, 2025 | €11.41M | +61.9% |
| Q1 FY2025 | Mar 31, 2025 | €12.32M | +32.7% |
| Q4 FY2024 | Dec 31, 2024 | €10.61M | +37.2% |
| Q3 FY2024 | Sep 30, 2024 | €9.41M | +72.9% |
| Q2 FY2024 | Jun 30, 2024 | €7.05M | +19.3% |
| Q1 FY2024 | Mar 31, 2024 | €9.28M | +53.2% |
| Q4 FY2023 | Dec 31, 2023 | €7.73M | -27.7% |
| Q3 FY2023 | Sep 30, 2023 | €5.45M | -64.5% |
| Q2 FY2023 | Jun 30, 2023 | €5.91M | -48.4% |
| Q1 FY2023 | Mar 31, 2023 | €6.06M | -54.7% |
| Q4 FY2022 | Dec 31, 2022 | €10.70M | -14.1% |
| Q3 FY2022 | Sep 30, 2022 | €15.35M | +38.0% |
| Q2 FY2022 | Jun 30, 2022 | €11.45M | +17.6% |
| Q1 FY2022 | Mar 31, 2022 | €13.37M | +50.1% |
| Q4 FY2021 | Dec 31, 2021 | €12.46M | +48.0% |
| Q3 FY2021 | Sep 30, 2021 | €11.12M | +34.0% |
| Q2 FY2021 | Jun 30, 2021 | €9.74M | +13.4% |
| Q1 FY2021 | Mar 31, 2021 | €8.91M | -30.6% |
| Q4 FY2020 | Dec 31, 2020 | €8.42M | -39.6% |
| Q3 FY2020 | Sep 30, 2020 | €8.30M | -25.0% |
| Q2 FY2020 | Jun 30, 2020 | €8.59M | -9.8% |
| Q1 FY2020 | Mar 31, 2020 | €12.83M | +7.2% |
| Q4 FY2019 | Dec 31, 2019 | €13.93M | +46.0% |
| Q3 FY2019 | Sep 30, 2019 | €11.07M | +75.9% |
| Q2 FY2019 | Jun 30, 2019 | €9.52M | +59.0% |
| Q1 FY2019 | Mar 31, 2019 | €11.96M | +58.4% |
| Q4 FY2018 | Dec 31, 2018 | €9.54M | – |
| Q3 FY2018 | Sep 30, 2018 | €6.30M | – |
| Q2 FY2018 | Jun 30, 2018 | €5.99M | – |
| Q2 FY2017 | Jun 30, 2017 | €7.55M | – |
See a number that looks wrong?